Recognized for continued investment into global infrastructure, technical expertise and personalized customer service, we have re-engineered our DNA with intense focus on advanced and emerging therapeutic and vaccine technologies. Through the strategic acquisition of premier industry CDMO specialists, Arranta Bio, Genibet, and Vibalogics we are even better able to address the complex requirements of novel molecule development and production. New biological modalities utilizing live-viruses- and vectors, live-microbial organisms, mRNA, plasmid DNA, and more, benefit from a commitment to services which strengthen the clinical-viability and commercial-sustainability of this class of products, often underserved due to demand on specialized expertise, and ability to manage unique complexity and customization required.

Customer-vendor relationships center around an education-first approach and consultative solution development, evaluating both the product and production process strategy, mitigating risks and eliminating challenges frequently seen in this dynamic segment of drug development. A comprehensive offering of non-GMP and GMP services for biological starting material generation, drug substance and drug product manufacture, quality control release testing, sterile fill-finish and delivery-device services support preclinical, through IND- to BLA- and commercial activities with collective experience encompassing successful filings across one-hundred regulatory agencies.

Ahead, and together, Recipharm’s advanced and emerging customers will leverage an existing global presence in both the US and EU (Boxborough & Watertown, MA; Cuxhaven, Germany, and Oeiras, Portugal), aided by a robust company-wide supply network and established synergy formed across technical laboratory and manufacturing operations, quality, and regulatory. As Recipharm expands its business ahead, customers will still find the same commitment to personalized service, and customizable and scalable end-to-end manufacturing solutions for which Recipharm and the acquired companies are known. Contact us today, and discover the genius of working together.